Cardiol Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
The last presentation of the day, but it is certainly one that I am enthusiastic about. Cardiol Therapeutics is the last presenting company for day one of the Cantor 2023 Global Healthcare Conference. And I continue to be Charles Duncan and I'm a biotech analyst at the firm, and happy to be here and excited to talk a little bit about Cardiol. Cardiol is a small company that is underknown, but it should be known better for its focus on developing cannabidiol, and specifically, a synthetic pharmaceuticalized version of cannabidiol, which is oh, by the way, delivered orally for cardio high value, high burden cardiovascular diseases.
And so this is a company that I've known for many years, I've known David Elsly, the company CEO, for many years, he is one of the founding of people in the company. And we also have Andrew Hamer, who is a card-carrying cardiologist and a person who've been involved in cardiac disease drug development for many years. They're going to run through a presentation of what Cardiol is doing, and I'll very likely in interrupt
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |